Glioblastoma | Norton Healthcare

Indication: Glioblastoma

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Sub-indication: CNS Cancer

Drug Study

Principal Investigator: Renato LaRocca, M.D.
Norton Cancer Institute

Sponsor: Sumitomo Dainippon Pharma Oncology, Inc.

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.